CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 10-Q: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -1.62.

EBIT: As of FY2025 Q2, the actual value is USD -6.353 M.

Segment Revenue

• Clinical Trial Supply Revenue: $0 for the six months ended June 30, 2025, compared to $33,000 for the same period in 2024.

Operational Metrics

• Net Loss: - $1,318,000 for the three months ended June 30, 2025, compared to - $3,257,000 for the same period in 2024.
• Research and Development Expenses: $68,000 for the three months ended June 30, 2025, compared to $2,023,000 for the same period in 2024.
• General and Administrative Expenses: $1,249,000 for the three months ended June 30, 2025, compared to $1,625,000 for the same period in 2024.
• Operating Loss: - $1,317,000 for the three months ended June 30, 2025, compared to - $3,644,000 for the same period in 2024.
• Gain on Deconsolidation of Subsidiary: $4,947,000 for the six months ended June 30, 2025.

Cash Flow

• Net Cash Used in Operating Activities: - $4,303,000 for the six months ended June 30, 2025, compared to - $3,567,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $5,526,000 for the six months ended June 30, 2025, compared to $6,210,000 for the same period in 2024.

Unique Metrics

• Stock-Based Compensation: $1,673,000 for the six months ended June 30, 2025, compared to $392,000 for the same period in 2024.

Future Outlook and Strategy

Core Business Focus

• The company plans to focus on the development of the plogosertib (“Plogo”) clinical program only, following the liquidation of its UK subsidiary, Cyclacel Limited.
• The company is investigating ways to raise additional capital through private equity financing or by entering into a strategic transaction to continue its operations and development activities.

Non-Core Business

• The company has no plans to repurchase any rights to or assets of the fadraciclib program, which is being marketed for sale by the joint liquidator.

Priority

• The company aims to complete the Exchange Agreement with FITTERS Diversified Berhad, which is expected to result in Fitters Sdn. Bhd becoming a wholly owned subsidiary and potentially increasing revenues in the fourth quarter of the year.